CFDB - Cystic Fibrosis DataBase

ongoing trials trial from

A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis - Phase 4 - Recruiting

Study design (if review, criteria of inclusion for studies)

This study is currently recruiting participants. - Verified July 2015 - Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment




Drug: Intermittent, short infusion Ceftazidime|Drug: Continuous infusion Ceftazidime|Drug: Intermittent, short infusion Meropenem|Drug: Continuous infusion Meropenem|Drug: Intermittent, short infusion Ticarcillin-clavulanate|Drug: Continuous infusion Ticarcillin-clavulanate|Drug: Intermittent, short infusion Cefepime|Drug: Continuous infusion Cefepime|Drug: Continuous infusion Piperacillin tazobactam|Drug: Intermittent, short infusion Piperacillin tazobactam

Outcome measures

Cystic Fibrosis Questionnaire-Revised respiratory component (CFQ-R) respiratory symptom score|Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory symptom score|Lung function testing, Forced volume expired in one second (FEV1)|C-reactive peptide (CRP)|Quantitative bacterial load in sputum (total + Pseudomonas aeruginosa)|Time above minimum inhibitory concentration (MIC)|Antibiotic stability|Pseudomonas aeruginosa virulence gene determinants

Keywords: Adult; Anti-Bacterial Agents; cefepime; Cephalosporins; Continuous; Intravenous; pharmacological_intervention; Bacterial Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Infection; Intermittent; Ceftazidime; Meropenem; Carbapenems; Ticarcillin; Penicillins; Piperacillin;